medigraphic.com

2015, Número 4

<< Anterior Siguiente >>

Med Sur 2015; 22 (4)


Enfermedad de Kawasaki: un vistazo al cincuenteno

Gámez-González LB, Yamazaki NMA

Idioma: Español
Referencias bibliográficas: 94
Paginas: 169-181
Archivo PDF: 173.95 Kb.


RESUMEN

La enfermedad de Kawasaki es una vasculitis sistémica que afecta principalmente a niños menores de cinco años de edad. El primer caso fue visto por el Dr. Tomisaku Kawasaki en 1961 y ya para 1967 fueron publicados los primeros 50 casos por él mismo. El diagnóstico se basa aún en las manifestaciones clínicas descritas en ese entonces. Su importancia radica en las secuelas coronarias que ocasiona, actualmente es la primera causa de cardiopatía adquirida en la población infantil. A 50 años de historia se revisan los aspectos de etiología, manifestaciones clínicas, diagnóstico y tratamiento de la enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [Japanese]. Arerugi 1967; 16: 178-222.

  2. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974; 54: 271-6.

  3. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, et al. Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease; Council on Cardiovascular Disease in the Young; American Heart Association; American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease.Circulation 2004; 110: 2747-71.

  4. Amano S, Hazama F, Hamashima Y. Pathology of Kawasaki disease: I. Pathology and morphogenesis of the vascular changes. Jpn Circ J 1979; 43: 633-43.

  5. Yanagisawa M, Kobayashi N, Matsuya S. Myocardial infarction due to coronary thromboarteritis, following acute febrile mucocutaneous lymph node syndrome (MLNS) in an infant. Pediatrics 1974; 54: 277-80.

  6. Kato H, Koike S, Yamamoto M, Ito Y, Yano E. Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome. J Pediatr 1975; 86: 892-8.

  7. Amano S, Hazama F, Hamashima Y. Pathology of Kawasaki disease: II. Distribution and incidence of the vascular lesions. Jpn Circ J 1979; 43: 741-8.

  8. Son MB, Newburger JW. Kawasaki disease. Pediatr Rev 2013; 34:151-62.

  9. Yamazaki Nakashimada MA. Enfermedad de Kawasaki. En: Berrón R. Enfermedades autoinmunitarias en niños. 1a. Ed. México, D.F.: Editorial Alfil; 2007, p. 151-60.

  10. Yamazaki-Nakashimada MA, Gámez González LB. Enfermedad de Kawasaki.Cap. Etiopatogenesis, Editorial Textos Mexicanos; 2015, p. 49-62.

  11. Lee KY, Han JW, Lee JS. Kawasaki disease may be a hyperimmune reaction of genetically susceptible children to variants of normal enviromental flora. Med hypotheses 2008; 69: 642-51.

  12. Kinumaki A, Sekizuka T, Hamada H, Kato K, Yamashita A, Kuroda M. Characterization of the gut microbiota of Kawasaki disease patients by metogenimoc analysis. Front Microbiol 2015; 6: 824.

  13. Shulman ST, Rowley AH. Kawasaki disease: insights into pathogenesis and approaches to treatment. Nat Rev Rheumatol 2015; 11(8): 475-82.

  14. Brogan PA, Shah V, Clarke LA, Dillon MJ, Klein N. T cell activation profiles in Kawasaki syndrome. Clin Exp Immunol 2008; 151: 267-74.

  15. Leung DY, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993; 342: 1385-8.

  16. Burgner D, Harnden A. Kawasaki disease what is the epidemiology telling us about the etiology? Int J Infect Dis 2005; 9: 185-94.

  17. Rowley AH, Eckerley CA, Jack HM, Shulman ST, Baker SC. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol 1997; 159: 5946-55.

  18. Rowley AH, Shulman ST, Garcia FL, Guzman-Cottrill JA, Miura M, Lee HL, Baker SC. Cloning the arterial IgA antibody response during acute Kawasaki disease. J Immunol 2005; 175: 8386-91.

  19. Rowley AH, Shulman ST, Mask CA, Finn LS, Terai M, Baker SC, Galliani CA, et al. IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J Infect Dis 2000; 182: 1183-91.

  20. Rowley AH, Shulman ST, Spike BT, Mask CA, Baker SC. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol 2001; 166: 1334-43.

  21. Fujita Y, Nakamura Y, Sakata K, Hara N, Kobayashi M, Nagai M, Yanagawa H, et al. Kawasaki disease in families. Pediatrics 1989; 84: 666-9.

  22. Uehara R, Yashiro M, Nakamura Y, Yanagawa H. Kawasaki disease in parents and children. Acta Paediatr 2003; 92: 694-97

  23. Rowley AH. Kawasaki disease: novel insights into etiology and genetic susceptibility. Annu Rev Med 2011; 62: 69-77.

  24. Onouchi Y, Ozaki K, Burns JC, Shimizu C, Terai M, Hamada H, Honda T, et al. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet 2012; 44: 517-21.

  25. Lee YC, Kuo HC, Chang JS, Chang LY, Huang LM, Chen MR, Liang CD, et al. Two new susceptibility loci for Kawasaki disease identified through genome wide association analysis. Nat Genet 2012; 44: 522-5.

  26. Rodó X, Curcoll R, Robinson M, Ballester J, Burns JC, Cayan DR, Lipkin WI, et al. Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan. Proc Natl Acad Sci USA 2014; 111: 7952-7.

  27. Singh S, Newburger JW, Kuijpers T, Burgner D. Management of Kawasaki Disease in resource limited settings. Pediatr Infect Dis J 2015; 34: 94-6.

  28. Saundankar J, Yim D, Itotoh B, Payne R, Maslin K, Jape G, Ramsay J, et al. The epidemiology and clinical features of Kawasaki disease in Australia. Pediatrics 2014; 133: e1009-e1014.

  29. Uehara R, Belay ED. Epidemiology of Kawasaki Disease in Asia, Europe, and the United States. J Epidemiol 2012; 22: 79-85.

  30. Makino N, Nakamura Y, Yashiro M, Ae R, Tsuboi S, Aoyama Y, Kojo T, et al. Descriptive Epidemiology of Kawasaki Disease in Japan, 2011–2012: From the Results of the 22nd Nationwide Survey. J Epidemiol 2015; 25: 239-45.

  31. Kim GB, Han JW, Park YW, Song MS, Hong YM, Cha SH, Kim DS, et al. Epidemiologic features of Kawasaki disease in South Korea: data from nationwide survey, 2009-2011. Pediatr Infect Dis J 2014; 33: 24-7.

  32. Singh S, Vignesh P, Burgner D. The epidemiology of Kawasaki disease: a global update. Arch Dis Child 2015; 100: 1084-8.

  33. Holman RC, Christensen KY, Belay ED, Steiner CA, Effler PV, Miyamura J, Forbes S, et al. Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii. Hawaii Med J 2010; 69: 194-7.

  34. Park YW, Han JW, Hong YM, Ma JS, Cha SH, Kwon TC, Lee SB, et al. Epidemiologic features of Kawasaki disease in Korea, 2006- 2008. Pediatr Int 2011; 53: 36-9.

  35. Rodó X, Ballester J, Cayan D, Melish ME, Nakamura Y, Uehara R, Burns JC. Association of Kawasaki disease disease with tropospheric wind patterns. Sci Rep 2011; 1: 152.

  36. Burns JC, Herzog L, Fabri O, Tremoulet AH, Rodó X, Uehara R, Burgner D. Seasonality of Kawasaki Disease: A Global Perspective. PLoS One 2013; 8(9): e74529.

  37. Jorquera H, Borzutzky A, Hoyos-Bachiloglu R, García A. Association of Kawasaki disease with tropospheric winds in Central Chile: is wind-borne desert dust a risk factor? Environ Int 2015; 78: 32-8.

  38. González-Mata A, Ulloa-Gutiérrez R, Brea J, Soza G, Tremoulet AH. Origin and importance of the Latin American Kawasaki Disease Network (REKAMLATINA). Rev Chilena Infectol 2013; 30: 402-4.

  39. Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki disease. Pediatrics 1978; 61: 100-7.

  40. Sasaguri Y, Kato H. Regression of aneurysms in Kawasaki disease: a pathological study. J Pediatr 1982;100: 225-31.

  41. Orenstein JM, Shulman ST, Fox LM, Baker SC, Takahashi M, Bhatti TR, Russo PA, et al. Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study. PLoS ONE 2012; 7: e38998

  42. Saltigeral SP, Garrido GLM, Camacho RL, Soto AK, Yamazaki NMA. Enfermedad de Kawasaki. ¿La fiebre debe ser un criterio obligatorio? Rev Alerg Mex 2008; 55: 176-9.

  43. Rodríguez-Lozano AL, Rivas-Larrauri FE, Hernández-Bautistan VM, Yamazaki-Nakashimada MA. Fever is not always present in Kawasaki disease. Rheumatol Int 2012; 32(9): 2953-4.

  44. Kuo HC, Yang KD, Chang WC, Ger LP, Hsieh KS. Kawasaki disease: An update on diagnosis and treatment. Pediatr Neonatol 2012; 53: 4-11.

  45. Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004; 364: 533e44.

  46. Gámez González LB, Yamazaki Nakashimada MA. Enfermedad de Kawasaki ¿Una enfermedad exótica y rara? Alergia, Asma e Inmunología Pediátricas 2012; 21: 22-35.

  47. García Pavón S, Staines Boone T, Hernández Bautista V, Yamazaki Nakashimada MA. Reactivation of the scar of BCG vaccination in Kawasaki Disease: clinical case and literature review. Rev Alerg Mex 2006; 53: 76-8.

  48. Cura MA, Haskal ZJ, Weintraub J, Benvenisty A. SIR 2004 film panel case: systemic artery aneurysms in Kawasaki disease. J Vasc Interv Radiol 2004; 15: 1009-11.

  49. Yacoe ME, Dake MD. Development and resolution of systemic and coronary artery aneurysms in Kawasaki disease. AJR 1992; 159: 708-10.

  50. Pires A, Sousa G, Castela E. Coronary and systemic aneurysms in an infant with Kawasaki. Pediatr Cardiol 2009; 30: 568-9.

  51. Suda K, Matsumura M, Ohta S. Kawasaki disease complicated by cerebral infarction. Cardiol Young 2003; 13: 103-5.

  52. Fujiwara S, Yamano T, Hattori M, Fujiseki Y, Shimada M. Asymptomatic cerebral infarction in Kawasaki disease. Pediatr Neurol 1992; 8: 235-6.

  53. Yamazaki-Nakashimada MA, Rivas-Larrauri F, Alcántara-Salinas A, Hernández-Bautista V, Rodríguez-Lozano AL. Brain hemorrhage in a patient with Kawasaki disease. Rev Alerg Mex 2013; 60: 38-40.

  54. Tanaka S, Sagiuchi T, Kobayashi I. Ruptured pediatric posterior cerebral artery aneurysm 9 years after the onset of Kawasaki disease: a case report. Childs Nerv Syst 2007; 23: 701-6.

  55. Ahn JH, Phi JH, Kang HS, Wang KC, Cho BK, Lee JY, Kim GB, et al.A ruptured middle cerebral artery aneurysm in a 13-monthold boy with Kawasaki disease.Case report.J Neurosurg Pediatr 2010; 6: 150-3.

  56. Yamazaki-Nakashimada MA, Espinosa-Lopez M, Hernandez- Bautista V, Espinosa-Padilla S, Espinosa-Rosales F. Catastrophic Kawasaki disease or juvenile Polyarteritis nodosa? Semin Arthritis Rheum 2006; 35: 349-54.

  57. Gámez-González LB, Rodríguez-Lozano A, Rivas-Larrauri F, Yamazaki- Nakashimada M, Kawasaki A. Disease and Henoch- Schönlein Purpura: Frequent Vasculitis in an Infrequent Association. Rev Alerg Mex 2012; 59: 37-40.

  58. Yim D, Curtis N, Cheung M, Burgner D. An update on Kawasaki disease II: Clinical features, diagnosis, treatment and outcomes. J Paediatr Child Health 2013; 49: 614-23.

  59. Rowley AH. Incomplete (atypical) Kawasaki disease. Pediatr Infect Dis J 2002; 21(6): 563-5.

  60. Rowler A. Pediatric vasculitis, an a Clinician pearls and myths in Rheumatology.Springer.Nueva York: Edit Stone; 2009, p. 211-8.

  61. Bajolle F, Laux D. Kawasaki Disease: what you need to know.Arch Pediatr 2012; 19: 1264-8.

  62. Freeman AF, Shulman ST. Kawasaki disease: Summary of the American Heart Association Guidelines. Am Fam Physician 2006; 74: 1141-8.

  63. Thabet F, Bafaqih H, Al-Mohaimeed S, Al-Hilali M, Al-Sewairi W, Chehab M. Shock: an unusual presentation of Kawasaki disease. Eur J Pediatr 2011; 170: 941-3.

  64. Kanegaye JT, Wilder MS, Molkara D, Frazer JR, Pancheri J, Tremoulet AH, Watson VE, et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics 2009; 123; 783-9.

  65. Dominguez SR, Friedman K, Seewald R, Anderson MS, Willis L, Glode MP. Kawasaki disease in a pediatric intensive care unit: A Case-control study. Pediatrics 2008; 122: 786-90.

  66. Gámez-González LB, Murata C, Muñoz-Ramírez M, Yamazaki- Nakashimada M. Clinical manifestations associated with Kawasaki disease shock syndrome in Mexican children. Eur J Pediatr 2013; 172: 337-42.

  67. Camacho-Lovillo MS, Melón M, Moreno MD, Ardanuy AV, Neth O. Kawasaki Disease Shock Syndrome (KDSS) Presentation of 3 children and Review of the Literature. Klin Padiatr 2015; 227: 355-7.

  68. Lin YJ, Cheng MC, Lo MH, Chien SJ.Early differentiation of Kawasaki Disease Shock Syndrome in a Pediatric Intensive Care Unit.Pediatr Infect Dis J 2015; 34: 1163-7.

  69. Latino GA, Manlhiot C, Yeung RS, Chahal N, McCrindle BW. Macrophage activation syndrome in the acute phase of Kawasaki disease.J Pediatr Hematol Oncol 2010; 32: 527-31.

  70. Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome after Kawasaki disease. Pediatr Infect Dis J 2003; 22: 663-6.

  71. al-Eid W, al-Jefri A, Bahabri S, al-Mayouf S. Hemophagocytosis complicating Kawasaki disease. Pediatr Hematol Oncol 2000; 17: 323-9.

  72. Suresh N, Sankar J. Macrophage activation syndrome: a rare complication of incomplete Kawasaki disease. Ann Trop Paediatr 2010; 30: 61-4.

  73. Chen Y, Shang S, Zhang C, Liu T, Yang Z, Tang Y. Hemophagocytic lymphohistiocytosis at initiation of kawasaki disease and their differential diagnosis. Pediatr Hematol Oncol 2010; 27: 244-9.

  74. Muise A, Tallett SE, Silverman ED. Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome? Pediatrics 2003; 112: e495.

  75. JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. Circ J 2014; 78: 2521-62.

  76. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, et al. The treatment of Kawasaki syndrome with intravenous gammaglobulin. N Engl J Med 1986; 315: 341-7.

  77. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633-9.

  78. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, Tamura T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984; 2: 1055-8.

  79. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997; 131: 888-93.

  80. Yamazaki NM, Hernaìndez BV, Espinosa PS, Espinosa RF. Corticoesteroides en la enfermedad de Kawasaki. Carta al Editor. Acta Pediatr Mex 2006; 27: 165-6.

  81. Son MB, Newburger JW. Management of Kawasaki disease: corticosteroids revisited. Lancet 2012; 379: 1571-2.

  82. Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012; 379: 1613-20.

  83. Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics 2012; 129: e17-e23.

  84. Inoue Y, Okada Y, Shinohara M, Kobayashi T, Kobayashi T, Tomomasa T, Takeuchi K, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr 2006; 149: 336-41.

  85. Yang X, Liu G, Huang Y, Chen S, Du J, Jin H.A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease. Cardiol Young 2015; 25: 1182-90.

  86. Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, Atz AM, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007; 356: 663-75.

  87. Hokosaki T, Mori M, Nishizawa T, Nakamura T, Imagawa T, Iwamoto M, Yokota S. Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease. Pediatr Int 2012; 54: 99-103.

  88. Lee TJ, Kim KH, Chun JK, Kim DS.Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med J 2008; 49: 714-8.

  89. Tremoulet AH, Pancoast P, Franco A, Bujold M, Shimizu C, Onouchi Y, Tamamoto A, et al. Calcineurin inhibitor treatment of intravenous immunoglobulin resistant Kawasaki disease. J Pediatr 2012; 161: 506-12.

  90. Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, Baker A, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr 2011; 158: 644-9.

  91. Choueiter NF, Olson AK, Shen DD, Portman MA. Prospective open-label trial of etanercept as adjunctive therapy for Kawasaki disease. J Pediatr 2010; 157: 960-6.

  92. Portman MA, Olson A, Soriano B, Dahdah N, Williams R, Kirkpatrick E. Etanercept as adjunctive treatment for acute Kawasaki disease: Study design and rationale. Am Heart J 2011; 161: 494-9.

  93. Shafferman A, Birmingham JD, Cron RQ. High dose anakinra for treatment of severe neonatal Kawasaki disease: a case report. Pediatr Rheumatol Online J 2014; 12: 26.

  94. Shirley DA, Stephens I. Primary treatment of incomplete Kawasaki disease with infliximab and methylprednisolone in a patient with a contraindication to intravenous immune globulin. Pediatr Infect Dis J 2010; 29: 978-9.




2020     |     www.medigraphic.com